A continual reassessment method without undue risk of toxicity

DOI10.1080/03610918.2021.1877306OpenAlexW3128946471MaRDI QIDQ6171847

Xikui Wang, Saman Muthukumarana, Weijia Zhang, Po Yang

Publication date: 18 July 2023

Published in: Communications in Statistics - Simulation and Computation (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1080/03610918.2021.1877306

zbMATH Keywords

Bayesian methodmaximum tolerated dosecontinual reassessment methodtoxicitydose findingphase i clinical trials

Mathematics Subject Classification ID

Statistics (62-XX)

Cites Work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• The treatment versus experimentation dilemma in dose finding studies
• Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
• Continual reassessment and related dose-finding designs
• Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
• Approximate dynamic programming and its applications to the design of Phase I cancer trials
• Optimal sequential designs in phase I studies
• Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
• Adaptive clinical trial designs for phase I cancer studies
• Design and Analysis of Phase I Clinical Trials
• Semiparametric Dose Finding Methods
• A new design of the continual reassessment method
• Simple benchmark for complex dose finding studies
• Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials

This page was built for publication: A continual reassessment method without undue risk of toxicity